2017.01.04
Microport® CardioFlow Completes Patient Enrollment of VitaFlow® Pre-market Clinical Trial
Shanghai, China - MicroPort® CardioFlow has recently completed the patient enrollment of the pre-market clinical trial of its self-developed VitaFlow® Transcatheter Aortic Valve and Delivery System ("VitaFlow®"), which is three months prior to the scheduled completion date. The clinical trial is a prospective, multi-center trial, aiming at assessing the safety and efficacyof VitaFlow® in the treatment of severe aortic stenosis. The clinical trial was organized by Professor Junbo Ge, an academician of Chinese Society of Sciences and a renowned cardiologist. Zhongshan Hospital of Fudan University, led eleven domestic hospitals to complete the clinical trial.
Read More
沪公网安备 31011502014876号
are registered trademarks of MicroPort CardioFlow Medtech Corporation.